New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Journal

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00130404-200609000-00003PMID 17034670
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Palonosetron

  2012cited by this paper
• Management of nausea and vomiting in cancer and cancer treatment

  2008cited by this paper
• (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis.

  2006cited by this paper
• Emerging drugs for chemotherapy-induced emesis

  2006cited by this paper
• Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

  2006cited by this paper
• Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets.

  2006cited by this paper
• Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy

  2005cited by this paper
• Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study

  2005cited by this paper
• Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress.

  2004influential reference
• Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons.

  2004cited by this paper
• Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.

  2004cited by this paper
• 5-HT3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis

  2004cited by this paper
• Costs and benefits of outpatient therapy

  2004cited by this paper
• Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.

  2003cited by this paper
• Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer.

  2003cited by this paper
• Cancer Care Ontario Practice Guidelines Initiative

  2003cited by this paper
• A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.

  2003cited by this paper
• Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

  2003cited by this paper
• Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics

  2003cited by this paper
• Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE).

  2003cited by this paper
• The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets.

  2002cited by this paper
• 5-HT(3) receptors mediate inflammation-induced unmasking of functional tachykinin responses in vitro.

  2002cited by this paper
• Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.

  2002cited by this paper
• The effects of nabumetone, a cyclooxygenase-2 inhibitor, on cisplatin-induced 5-hydroxytryptamine release from the isolated rat ileum.

  2001cited by this paper
• Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.

  2001cited by this paper
• Central neurocircuitry associated with emesis.

  2001influential reference
• Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors.

  2001influential reference
• Δ9-Tetrahydrocannabinol and Synthetic Cannabinoids Prevent Emesis Produced by the Cannabinoid CB1 Receptor Antagonist/Inverse Agonist SR 141716A

  2001cited by this paper
• Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.

  2001cited by this paper
• Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy‐induced nausea and vomiting

  2000cited by this paper
• Serotonin unmasks functional NK‐2 receptors in vagal sensory neurones of the guinea‐pig

  1999cited by this paper
• Effects of N-methyl-D-aspartate receptor antagonists on cisplatin-induced emesis in the ferret.

  1996cited by this paper
• The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro

  1995cited by this paper
• Costs and benefits of outpatient therapy

  1994cited by this paper
• The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret.

  1993cited by this paper
• Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets.

  1993cited by this paper
• Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret.

  1993cited by this paper
• Mechanisms by which cancer chemotherapeutic drugs induce emesis.

  1992cited by this paper
• Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism

  1986influential reference
• Peptide-induced emesis in dogs.

  1984cited by this paper
• Metoclopramide. A review of antiemetic trials.

  1983cited by this paper
• Pharmacological analysis of the effects of metoclopramide on the guinea-pig ileum in vitro.

  1973cited by this paper
• Effects of metoclopramide on isolated guinea-pig colon. 1. Peripheral sensitization to acetylcholine.

  1970cited by this paper
• Effects of metoclopramide on isolated guinea-pig colon. 2. Interference with ganglionic stimulant drugs.

  1970cited by this paper
• Observations on the Release and Turnover Rate of 5‐Hydroxytryptamine in the Gastrointestinal Tract

  1959cited by this paper

• Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting.

  2022cites this paper
• Vomiting and Nausea

  2021cites this paper
• Involvement of 5-Serotonin and Substance p Pathways in Dichroa Alkali Salt-Induced Acute Pica in Rats

  2021cites this paper
• Nanotechnology based blended chitosan-pectin hybrid for safe and efficient consolidative antiemetic and neuro-protective effect of meclizine hydrochloride in chemotherapy induced emesis.

  2020cites this paper
• Translational and Randomized Study of 5-HT3 Receptor Antagonists for Evaluation of Chemotherapy-induced Nausea and Vomiting Related Biomarkers.

  2019cites this paper
• Supportive Care Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

  2018cites this paper
• Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance.

  2017cites this paper
• Nausea and vomiting of pregnancy - What's new?

  2017cites this paper
• A review on hormonal complications of gastrointestinal system and its treatment during prenatal period

  2017cites this paper
• Efektifitas Pemberian Omeprazole pada Ondansetron dalam Tatalaksana Mual Muntah Akibat Kemoterapi Kanker Anak

  2016cites this paper
• Prevention of Nausea and Vomiting in Oncology

  2016cites this paper
• The Gastrointestinal Tract and the Liver in Pregnancy: Normal Functions and Diseases

  2015cites this paper
• Plasma serotonin levels are elevated in pregnant women with hyperemesis gravidarum

  2015cites this paper
• Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy‐induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients

  2015cites this paper
• Pharmacogenetics of chemotherapy-induced nausea and vomiting.

  2015cites this paper
• Approach to Gastrointestinal and Liver Diseases in Pregnancy

  2015cites this paper
• Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region

  2014cites this paper
• Anticipatory nausea and vomiting due to chemotherapy.

  2014cites this paper
• Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

  2014influential citation
• Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

  2013cites this paper
• Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives

  2013cites this paper
• Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers

  2013cites this paper
• Netupitant PET imaging and ADME studies in humans

  2013cites this paper
• Palonosetron for the prevention of chemotherapy-induced nausea and vomiting

  2013cites this paper
• Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.

  2012influential citation
• Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial

  2012cites this paper
• Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics

  2011influential citation
• Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study

  2011cites this paper
• Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

  2011cites this paper
• Nausea and vomiting of pregnancy.

  2011cites this paper
• Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.

  2010cites this paper
• Approach to Hyperemesis Gravidarum

  2010cites this paper
• Managing chemotherapy-induced nausea and vomiting in oncology patients

  2009cites this paper
• Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.

  2009cites this paper
• Symptom Management in Children with Cancer

  2009cites this paper
• Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting.

  2009cites this paper
• A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.

  2008cites this paper
• [History and new developments. The pharmacology of 5-ht3 antagonists].

  2007cites this paper
• Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007.

  2007cites this paper
• A histologically derived stereotaxic atlas and substance P immunohistochemistry in the brain of the least shrew (Cryptotis parva) support its role as a model organism for behavioral and pharmacological research.

  2007cites this paper
• New anti-emetic treatments.

  2007cites this paper
• Pharmakologie der 5-HT3-Antagonisten. Historie und neue Entwicklungen

  2007cites this paper
• Are Neuropeptides Important in Arthritis?

  2007cites this paper
• Is there a need to identify new anti-emetic drugs?

  2007cites this paper
• A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.

  2006cites this paper
• Cancer Management and Research Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Prevention of Acute Chemotherapy-induced Nausea and Vomiting: the Role of Palonosetron

  year unknowncites this paper